针对卡帕阿片类受体进行止痛和抗瘤作用
David G Lambert1, Joshua S Mincer2
1Department of Cardiovascular Sciences, Anaesthesia, Critical Care and Pain Management, University of Leicester, Hodgkin Building, Leicester, UK.
British journal of anaesthesia
|January 8, 2025
概括
卡帕阿片类药物 (KOP) 受体激动剂显示,除了缓解疼痛之外,它还具有前景. 研究表明,KOP受体的激活会诱导质瘤细胞死亡,这表明它有可能作为一种新的癌症治疗辅助剂.
科学领域:
- 神经科学和瘤学
- 分子生物学和药理学 分子生物学和药理学
背景情况:
- 卡帕阿片类 (KOP) 受体激动剂以镇痛特性而闻名,但由于中心副作用而面临限制.
- 新兴研究强调了阿片类受体的非止痛作用,促使研究新的治疗应用.
- 在质瘤组织中高KOP受体表达与改善患者存活率有关.
研究的目的:
- 为了研究KOP受体激素的潜力,作为质瘤的治疗策略.
- 探索KOP受体激活影响质瘤细胞亡的机制.
主要方法:
- 对质瘤组织中KOP受体表达的分析.
- 对KOP受体激素对质瘤细胞亡的影响的评估.
- 研究p38 MAPK通路对KOP受体介导作用的参与.
主要成果:
- 在质瘤中高KOP受体表达与改善患者存活率之间发现了相关性.
- 已经证明,KOP受体的激动性促进了质瘤细胞的亡.
- 通过调节p38 MAPK瘤性途径,KOP受体激素的亲亡效应得到了调节.
结论:
- KOP受体连接体代表了质瘤治疗的有前途的治疗途径.
- KOP受体激动剂可以作为有效的化疗辅助剂,增强质瘤细胞死亡.
- 准KOP受体及其下游通路为癌症治疗提供了一种新的策略.
相关概念视频
Analgesia and Pain Management
490
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
490
Opioid Receptors: Overview
501
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
501
Opioid Analgesics: Synthetic and Semisynthetic Opioids
218
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
218
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
201
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
201


